Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence - Full Text View

Sponsored by:	Cardiome Pharma
Information provided by:	Cardiome Pharma
ClinicalTrials.gov Identifier:	NCT00267930

Purpose

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

Condition	Intervention	Phase
Atrial Fibrillation	Drug: Vernakalant (oral) Drug: Placebo comparator	Phase II

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome

Drug Information available for: RSD 1235

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF

Further study details as provided by Cardiome Pharma:

Primary Outcome Measures:

All subjects who were exposed to the investigational medication were evaluated for safety. [ Time Frame: Subjects were assessed for safety within Day 58 of dosing ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Recurrence of AF/AFL or withdrawal [ Time Frame: Time for recurrence of AF/AFL or withdrawal within Day 28 of dosing ] [ Designated as safety issue: No ]
Improvement in AF symptoms [ Time Frame: Time to improvement in AF symptoms within Day 28 of dosing ] [ Designated as safety issue: No ]

Enrollment:	221
Study Start Date:	December 2005
Study Completion Date:	August 2006

Arms	Assigned Interventions
1: Placebo Comparator Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d	Drug: Placebo comparator
2: Experimental Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d	Drug: Vernakalant (oral)
3: Experimental Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d	Drug: Vernakalant (oral)

Eligibility

Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria (partial list):

Subjects must have sustained, symptomatic atrial fibrillation for greater than 72 hours and less than 6 months duration
Subjects must have adequate anticoagulant therapy

Exclusion Criteria (partial list):

Subjects may not have Class III or Class IV congestive heart failure
Subjects may not have uncorrected electrolyte imbalance

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00267930

Locations

United States, Alabama
The Heart Center, P.C.
Huntsville, Alabama, United States, 35801
United States, California
Cardiovascular Consultants Medical Group, Inc.
Walnut Creek, California, United States, 94598
United States, Pennsylvania
Penn State Heart & Vascular Institute
Hershey, Pennsylvania, United States, 17033
United States, Wisconsin
Marshfield Clinic
Marshfield, Wisconsin, United States, 54449
Canada, Alberta
Foothills Hospital
Calgary, Alberta, Canada, T2N 2T9
Canada, Quebec
Centre Hospitalier de l'Université de Montréal (CHUM) Hôtel Dieu
Montréal, Quebec, Canada, H2W 1T8
Denmark
Bispebjerg Hospital
Kobenhavn, Denmark
KAS Gentofte Kardiologisk Afdeling
Hellerup, Denmark
Medicinsk Afdeling Kolding Sygehus
Kolding, Denmark, 6000
Aalborg Sygehus Syd
Aalborg, Denmark, 9100
Aarhus Sygehus Kardiologisk Afd. A
Aarhus, Denmark, 8000
Kardiologisk/endokrinologisk afd. E Frederiksberg Hospital
Frederiksberg, Denmark, 2000
Roskilde Amts Sygehus Koge
Koge, Denmark, 4600
Sygehus Vendsyssel Hjorring
Hjorring, Denmark, 9800
KAS Herlev
Herlev, Denmark, 2730
Netherlands
Catharina Ziekenhuis
Eindhoven, Netherlands
University Medical Center Groningen (UMCG)
Groningen, Netherlands
Stichting Sint Antonius Ziekenhuis
Nieuwegein, Netherlands
Trial sectie Cardiologie
Heerlen, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
Reinier de Graaf Gasthuis
Delft, Netherlands
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands

Sponsors and Collaborators

Cardiome Pharma

Investigators

Study Director:

Greg Beatch, PhD

Cardiome Pharma

More Information

Related Info This link exits the ClinicalTrials.gov site

Responsible Party:	Cardiome Pharma Corp. ( Gregory Beatch, Ph.D., Vice President, Scientific Affairs )
Study ID Numbers:	1235-SR-1005
Study First Received:	December 20, 2005
Last Updated:	December 17, 2008
ClinicalTrials.gov Identifier:	NCT00267930
Health Authority:	United States: Food and Drug Administration; Canada: Health Canada; Bulgaria: Ministry of Health; Czech Republic: State Institute for Drug Control; Denmark: Danish Medicines Agency; Denmark: Ethics Committee; Hungary: National Institute of Pharmacy; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); Russia: Ministry of Health and Social Development of the Russian Federation; Sweden: Medical Products Agency; Ukraine: Ministry of Health

Keywords provided by Cardiome Pharma:

AFib
AF

Study placed in the following topic categories:

Heart Diseases
Atrial Fibrillation
Recurrence
Atrial Flutter
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009